SIR, In many previous studies, rheumatoid arthritis (RA) has been found at high frequencies in individuals with periodontitis, and RA resembles periodontitis in many pathological aspects [1, 2] . HLA-DR4 tissue antigens are found at high frequencies both in patients with periodontitis and in those with RA. HLA-DR4 tissue antigens and their subtypes are directly associated with each disease [3, 4] .
High levels of oral anaerobic bacterial antibodies and heatshock proteins have been found in the serum and synovial fluid of RA patients [5, 6] . Ornidazole is a nitroimidazole antiprotozoal drug that also has potent antibacterial activity against anaerobes, including Bacteroides and Clostridium species.
This was a 3-month, randomized, double-blind, placebocontrolled study. A total of 160 patients (median age 53 yr, range 19-69, 125 female) with active RA were randomly assigned to receive 1000 mg ornidazole (n ¼ 53), 500 mg ornidazole (n ¼ 55) or placebo (n ¼ 52). Patients enrolled in this study met the American College of Rheumatology (ACR) criteria for the diagnosis of RA. This study was approved by the local ethics committee and was carried out in accordance with the ethical principles of the Declaration of Helsinki. Before entering this study, all patients gave informed consent.
The percentage change from baseline to 3 months in the swollen joint count and tender joint count was the primary measure of efficacy. Secondary end-points included pain, quality of life, duration of morning stiffness, erythrocyte sedimentation rate, Creactive protein level, and physician's and patient's global assessments. The data were also analysed to determine the numbers of patients meeting ACR criteria for 20, 50 and 70% improvement. The values were compared using analysis of variance. and patient's global assessments, and significant reductions in disease activity as assessed by objective laboratory measures (erythrocyte sedimentation rate and C-reactive protein level) ( Table 1) . Ornidazole was well tolerated. There were no doselimiting toxic effects. The most frequently reported adverse events in the 1000-and 500-mg ornidazole treatment groups (seen in at least 5% of patients, and excluding worsening of RA) were headache (18.9 and 14.5%, respectively), dry mouth (16.7 and 12.3%, respectively) and nausea (13.2 and 9.1%, respectively). The results of this randomized, double-blind trial show the clinical efficacy of ornidazole in patients with active RA. Treatment with ornidazole for 3 months was associated with a reduction in disease activity, as assessed by a number of clinical end-points, biochemical markers of disease and quality of life.
Ornidazole produced significant and sustained reductions in disease activity. The few adverse events noted-headache, dry mouth and nausea-were mild and easily managed.
Ornidazole, a synthetic nitroimidazole derivative, is used in the treatment of infections caused by periodontopathic bacteria. Porphyromonas gingivalis, Prevotella intermedia, Prevotella melaninogenica and Bacteroides forsythus are Gram-negative anaerobic bacteria and are considered to be directly responsible for the periodontitis (periodontopathic bacteria).
P. gingivalis has arginine-and lysine-specific proteinases. The citrullination or deamination of arginine residues in autoantigenic proteins (profilaggrin/filaggrin, fibrinogen/fibrin, keratin and vimentin) creates epitopes that are targeted by rheumatoid autoantibodies [7] . Arginine is the most important of the amino acids associated with autoantigenicity in proteins.
RA patients have significantly fewer galactose residues on their IgG Fc compared with age-matched healthy control subjects. A lack of terminal galactose residues early in disease is associated with a worse prognosis [8] . Prevotella melaninogenica, as a saccharolytic bacteria, disintegrates galactose. Consequently, P. melaninogenica causes this condition by binding to the Fc region of the IgG molecule and metabolizing galactose with its enzymes.
P. melaninogenica and P. intermedia heat shock proteins of approximately 70 kDa have been found in periodontal disease processes [9] . Hsp 70 antibodies have been detected in the synovial tissue of RA patients, and when the hsp 70 expression is induced with certain stress-stimulating factors, pro-inflammatory cytokines (TNF , IL-1, IL-6) develop in the RA synovium [10] .
Ornidazole treatment in RA is very economical compared with other treatments. It can be concluded from this study that ornidazole is an effective treatment for RA. The above evidence indicates that antibodies formed against oral anaerobic bacteria could be important in the aetiopathogenesis of RA. However, further studies are needed to confirm this. Correspondence to: M. Ogrendik, Altintas mah. Kocacami cad., Erten Kocabay Apt., No. 2, Kat:6, 09800, Nazilli-Aydin, Turkey. E-mail: mogrendik@hotmail.com Two-and three-dimensional Doppler sonographic evaluation of the effect of local cryotherapy on synovial perfusion in wrist arthritis SIR, Physical treatment including local cold and heat application has been used since antiquity in patients with arthritis. Both methods are known to relieve pain and improve disability in different stages of various rheumatic diseases. An analgesic effect can be readily accomplished after 3 min of local cryotherapy by destimulating pain receptors, which are located in the subcutis. Antiphlogistic effects are obtained after cold application for 20 min and longer by vasoconstriction, by inhibiting the cellular metabolism in the inflammatory cells and by repressing the release of lysosomal enzymes [1, 2] . Whereas the effects of local cold treatment inside the cutis and subcutis have been investigated extensively, not much is known about the influence of cryotherapy inside the affected and inflamed joints themselves. In a study by Oosterveld and Rasker [3] in which a temperature probe was positioned inside the knee joint cavity of patients with rheumatoid arthritis (RA), a decrease in temperature not only in the skin and superficial tissues but also inside the joint cavity could be verified.
Imaging procedures such as high resolution grey-scale ultrasound and power Doppler ultrasonography (PDUS) including three-dimensional (3D) mode have enlarged the diagnostic spectrum by direct visualization of pathomorphologic synovial changes in rheumatic diseases [4, 5] . PDUS had already been used to assess a decrease of synovial vascularization during anti-inflammatory therapy with TNF-inhibitors or after intra-articular steroid injection [6, 7] . In a small pilot study, we analysed the possibility to
